Project Grant R01HL174473
Award Date
6/5/25
Completion Date
3/31/29
Dollars Obligated
$741K
Federal Agency
National Heart Lung and Blood Institute
Federal Grant Program
93.837
Assistance Type
Project Grant
Place of Performance
Ohio, USA
Similar Awards
This federal Project Grant award R01HL174049, in the amount of $777,277.00, was awarded by the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research (CFDA 93.837) program. The funding will support research to elucidate the impact of genetic regulation of regulatory T cell (Treg) CD39 expression on the resolution of cardiac inflammation following myocardial infarction. The project aims to determine how CD39 activity on Tregs impacts cardiac inflammation...
This $144,362 Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) aims to investigate the immunologic mechanisms underlying the development of Chagas cardiomyopathy, a debilitating heart condition that affects 30-40% of individuals infected with Trypanosoma cruzi. The research will use advanced techniques like single-cell RNA sequencing and spatial transcriptomics to characterize the immune cell...
This federal Project Grant award, with ID R01HL174996, was provided by the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837). The $699,133 award supports research to understand the epigenetic regulation and transcriptomic reprogramming that underlie the development of heart failure with preserved ejection fraction (HFPEF) across multiple organ systems, including the heart, kidney, and liver. The researchers will leverage a rat...
The National Heart, Lung, and Blood Institute (NHLBI) awarded a $817,208 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to The Broad Institute, Inc. The grant will fund research to investigate the genetic basis and underlying mechanisms of heart failure using high-throughput cellular assays. The research aims to accelerate the functional interpretation of genes associated with heart failure risk identified through genome-wide association studies. The project...
This $500,089.80 federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) will support research to investigate the role of inflammatory macrophages in cardiac remodeling and diastolic dysfunction associated with heart failure with preserved ejection fraction (HFPEF). The research aims to uncover the molecular, cellular, and functional mechanisms by which macrophages mediate fibroblast differentiation...
This $655,636 Project Grant awarded by the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) will fund research conducted by the Texas Heart Institute to investigate the mechanisms of heart failure in patients with single ventricle congenital heart disease. The research objectives are to: 1) Examine the molecular drivers of cardiac fibroblast senescence in single ventricle heart failure patients, 2) Investigate the metabolic remodeling of cardiac...
The National Heart, Lung, and Blood Institute (NHLBI) awarded a $2,183,648 Project Grant under the Cardiovascular Diseases Research Program (CFDA 93.837) to Northwestern University. The grant, with a period of performance from February 1, 2025 to January 31, 2032, supports research to investigate key immunometabolic signaling pathways and crosstalk between macrophages and other cell types that contribute to chronic cardiac inflammation and heart failure. The research aims to improve...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $772,808 to Temple University to investigate the role of cardiomyocyte glutamine synthesis in heart failure development and progression. The research aims to determine if targeting cardiomyocyte glutamine production can reduce fibrosis, improve bioenergetics and redox balance, and serve as a therapeutic strategy for both heart failure...
The National Heart, Lung, and Blood Institute (NHLBI) awarded a $102,495 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to The Washington University in St. Louis to investigate the cardiac effects of combined OX40 activation and PD-1 inhibition, a new combination immunotherapy. The key objectives are to: 1) examine how cardiac T-cells respond to this therapy and reshape the cardiac immune landscape, 2) determine how the reshaped T-cell landscape modulates monocyte...
This $653,854 Project Grant was awarded by the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837). The purpose of the grant is to study the impact of cardiomyocyte-selective modulation of natriuretic peptide signaling pathways on cardiomyopathy progression and ventricular arrhythmia susceptibility in preclinical models. The specific aims are to: 1) Define how cardiomyocyte-specific modulation of PKG1 activity modifies cardiomyopathy...